BioSpace News Archive

Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced financial results for the second quarter ended June 30, 2022.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company, announced that Aziyo co-founder C. Randal Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), announces that the primary endpoint was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 study (clinicaltrials.gov, NCT 05003531) of picankibart (R&D code: IBI112), a recombinant anti-interleukin 23p19 subunit antibody injection, in Chinese patients with moderate-to-severe plaque psoriasis.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced the pricing of an upsized underwritten public offering of 3,488,373 shares of its common stock at a public offering price of $215.00 per share.

iNtRON Biotechnology announced that iNtRON has developed its unique CRISPR/Cas system customized for the genetic modification of certain bacteria and corresponding bacteriophage.

Taro Pharmaceuticals Inc. is recalling all lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because they may contain particulate matter.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, announced that it will be discontinuing its work with the U.S. Department of Defense under a prototype research and development agreement.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the second quarter 2022 and provided a corporate update.

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.